Potassium citrate

Identification

Name
Potassium citrate
Accession Number
DB09125
Description

Potassium citrate (also known as tripotassium citrate) is a potassium salt of citric acid. It is a white, hygroscopic crystalline powder. It is odorless with a saline taste. It contains 38.3% potassium by mass. In the monohydrate form it is highly hygroscopic and deliquescent. Potassium citrate is used to treat a kidney stone condition called renal tubular acidosis. Potassium Citrate is indicated also for the management of Hypocitraturic calcium oxalate nephrolithiasis.

Type
Small Molecule
Groups
Approved, Investigational, Vet approved
Structure
Thumb
Weight
Average: 306.394
Monoisotopic: 305.89464697
Chemical Formula
C6H5K3O7
Synonyms
  • Potassium citrate anhydrous
  • Tripotassium citrate

Pharmacology

Indication

For the management of renal tubular acidosis, hypocitraturic calcium oxalate nephrolithiasis, and uric acid lithiasis with or without calcium stones.

Associated Conditions
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics

Potassium citrate induces changes in the urine which renders urine less susceptible to the formation of crystals and stones from salts e.g. calcium oxalate, calcium phosphate and uric acid. Increased citrate levels in the urine will make complexation with calcium which decrease the calcium ion activity and decrease the chance for the formation of calcium phosphate crystals. Citrate also inhibits the spontaneous nucleation of calcium oxalate and calcium phosphate.

Mechanism of action

After oral administration of potassium citrate, its metabolism yields alkaline load. Potassium Citrate therapy appears to increase urinary citrate mainly by modifying the renal handling of citrate, rather than by increasing the filtered load of citrate. In addition to raising urinary pH and citrate, Potassium Citrate increases urinary potassium by approximately the amount contained in the medication. In some patients, Potassium Citrate causes a transient reduction in urinary calcium.

Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Potassium Citrate is absorbed and the citrate is metabolised to bicarbonate.

Route of elimination

Urinary; less than 5% unchanged.

Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity

LD50 (dog): Intravenous 176 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirPotassium citrate may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.
AbciximabThe risk or severity of bleeding can be increased when Abciximab is combined with Potassium citrate.
AcarbosePotassium citrate may increase the excretion rate of Acarbose which could result in a lower serum level and potentially a reduction in efficacy.
AcebutololAcebutolol may increase the hyperkalemic activities of Potassium citrate.
AceclofenacThe risk or severity of bleeding and hemorrhage can be increased when Aceclofenac is combined with Potassium citrate.
AcemetacinThe therapeutic efficacy of Potassium citrate can be decreased when used in combination with Acemetacin.
AcenocoumarolThe risk or severity of bleeding can be increased when Acenocoumarol is combined with Potassium citrate.
AcetaminophenPotassium citrate may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Potassium citrate.
AclidiniumPotassium citrate may increase the excretion rate of Aclidinium which could result in a lower serum level and potentially a reduction in efficacy.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
  • Take with food. Take potassium citrate within 30 minutes of eating to limit gastrointestinal irritation.

Products

Product Ingredients
IngredientUNIICASInChI Key
Potassium citrate monohydrateEE90ONI6FF6100-05-6PJAHUDTUZRZBKM-UHFFFAOYSA-K
Active Moieties
NameKindUNIICASInChI Key
Potassium cationionic295O53K15224203-36-9NPYPAHLBTDXSSS-UHFFFAOYSA-N
Citric acidunknownXF417D3PSL77-92-9KRKNYBCHXYNGOX-UHFFFAOYSA-N
Product Images
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Potassium CitrateTablet5 meq/1OralUpsher-Smith Laboratories, LLC2006-09-01Not applicableUS flag00245 0070 11 nlmimage10 234691d4
Potassium CitrateTablet10 meq/1OralUpsher-Smith Laboratories, LLC2006-09-01Not applicableUS flag00245 0071 11 nlmimage10 f00df86f
Urocit KTablet, extended releaseOralMission Pharmacal Company1995-01-01Not applicableCanada flag
Urocit-KTablet, extended releaseOralMission Pharmacal Company2011-02-11Not applicableCanada flag
Urocit-KTablet, extended release15 meq/1OralPhysicians Total Care, Inc.2010-09-15Not applicableUS flag00178 0615 01 nlmimage10 581dac0d
Urocit-KTablet, extended release10 meq/1OralMission Pharmacal Company1992-09-01Not applicableUS flag
Urocit-KTablet, extended release10 meq/1OralPhysicians Total Care, Inc.2003-04-17Not applicableUS flag
Urocit-KTablet, extended release10 meq/1OralREMEDYREPACK INC.2016-12-272018-01-19US flag
Urocit-KTablet, extended release5 meq/1OralMission Pharmacal Company1985-09-01Not applicableUS flag
Urocit-KTablet, extended release15 meq/1OralMission Pharmacal Company2010-01-27Not applicableUS flag0178 061520180907 15195 1ux5bno
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Potassium CitrateTablet, extended release5 meq/1OralZydus Pharmaceuticals (USA) Inc.2014-08-12Not applicableUS flag
Potassium CitrateTablet, extended release15 meq/1OralCadila Healthcare Limited2014-08-12Not applicableUS flag
Potassium CitrateTablet, extended release5 meq/1OralActavis Pharma, Inc.2018-05-30Not applicableUS flag
Potassium CitrateTablet, extended release540 mg/1OralMed-Health Pharma, LLC.2011-04-102012-04-25US flag
Potassium CitrateTablet, extended release15 meq/1OralZydus Pharmaceuticals (USA) Inc.2014-08-12Not applicableUS flag
Potassium CitrateTablet, extended release540 mg/1OralRising Pharmaceuticals2006-06-192011-02-03US flag
Potassium CitrateTablet, extended release15 meq/1OralANI Pharmaceuticals, Inc.2020-03-16Not applicableUS flag
Potassium CitrateTablet, extended release15 meq/1OralActavis Pharma, Inc.2018-05-30Not applicableUS flag
Potassium CitrateTablet, extended release10 meq/1OralCadila Healthcare Limited2014-08-12Not applicableUS flag
Potassium CitrateTablet, extended release1080 mg/1OralPhysicians Total Care, Inc.2006-07-24Not applicableUS flag
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
B6 Plus TabPotassium citrate (50 mg) + Magnesium oxide (50 mg) + Niacin (20 mg) + Pyridoxine hydrochloride (50 mg) + Riboflavin (2.4 mg) + Thiamine (10 mg)TabletOralVita Health Products Inc1979-12-312002-08-01Canada flag
Formula No. 2 Plus K LiqPotassium citrate (19.5 mg) + Ascorbic acid (2 mg)LiquidOralGolden Pride/Rawleigh1993-12-311996-09-30Canada flag
LytrenPotassium citrate (270 mg) + Citric acid (26 mg) + Dextrose, unspecified form (2 g) + Sodium chloride (263 mg) + Sodium citrate (49 mg)LiquidOralMead Johnson Nutritionals1985-12-312003-07-08Canada flag
Lytren Rhs LiqPotassium citrate (217 mg) + Citric acid (26.1 mg) + Sodium chloride (375 mg) + Sodium citrate (107 mg)LiquidOralMead Johnson Nutritionals1990-12-312000-09-11Canada flag
RehydralytePotassium citrate (2.04 mg) + Dextrose, unspecified form (25 mg) + Sodium chloride (3.8 mg) + Sodium citrate (.78 mg)LiquidOralRoss Laboratories, Division Of Abbott Laboratories Ltd.1988-12-312008-04-16Canada flag
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Cytra 3Potassium citrate (550 mg/5mL) + Citric acid monohydrate (334 mg/5mL) + Sodium citrate (500 mg/5mL)SyrupOralPegasus Laboratories2006-05-052009-10-17US flag
Cytra 3Potassium citrate (550 mg/5mL) + Citric acid monohydrate (334 mg/5mL) + Sodium citrate (500 mg/5mL)SyrupOralCypress Pharmaceuticals, Inc2008-07-292014-10-11US flag
Cytra-KPotassium citrate (1100 mg/5mL) + Citric acid monohydrate (334 mg/5mL)SolutionOralCypress Pharmaceuticals, Inc.2008-09-302014-10-11US flag
Cytra-K CrystalsPotassium citrate (3.3 g/1) + Citric acid monohydrate (1.002 g/1)Granule, for solutionOralCypress Pharmaceuticals, Inc.2003-05-01Not applicableUS flag
Potassium Citrate and Citric AcidPotassium citrate (1100 mg/5mL) + Citric acid monohydrate (334 mg/5mL)SolutionOralPharmaceutical Associates, Inc.1997-10-07Not applicableUS flag
Potassium Citrate Citric Acid CrystalsPotassium citrate (3.3 g/1) + Citric acid monohydrate (1.002 g/1)Granule, for solutionOralVirtus Pharmaceuticals LLC2014-06-132019-04-30US flag
Potassium Citrate-Citric AcidPotassium citrate (1100 mg/5mL) + Citric acid monohydrate (334 mg/5mL)SolutionOralMethod Pharmaceuticals2014-10-202015-12-31US flag
Potassium Citrate-Citric AcidPotassium citrate (1100 mg/5mL) + Citric acid monohydrate (334 mg/5mL)SolutionOralMethod Pharmaceuticals2015-12-212016-03-03US flag
Potassium Citrate-Sodium Citrate-Citric AcidPotassium citrate (550 mg/5mL) + Citric acid monohydrate (334 mg/5mL) + Sodium citrate dihydrate (500 mg/5mL)SolutionOralMethod Pharmaceuticals2015-12-212016-03-03US flag
Potassium Citrate-Sodium Citrate-Citric AcidPotassium citrate (550 mg/5mL) + Citric acid monohydrate (334 mg/5mL) + Sodium citrate dihydrate (500 mg/5mL)SolutionOralMethod Pharmaceuticals2014-10-202015-12-31US flag

Categories

ATC Codes
A12BA02 — Potassium citrate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as tricarboxylic acids and derivatives. These are carboxylic acids containing exactly three carboxyl groups.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Tricarboxylic acids and derivatives
Direct Parent
Tricarboxylic acids and derivatives
Alternative Parents
Tertiary alcohols / Carboxylic acid salts / Carboxylic acids / Organic potassium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Alcohol / Aliphatic acyclic compound / Carbonyl group / Carboxylic acid / Carboxylic acid salt / Hydrocarbon derivative / Organic alkali metal salt / Organic oxide / Organic oxygen compound / Organic potassium salt
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
potassium salt (CHEBI:64733)

Chemical Identifiers

UNII
86R1NVR0HW
CAS number
866-84-2
InChI Key
QEEAPRPFLLJWCF-UHFFFAOYSA-K
InChI
InChI=1S/C6H8O7.3K/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3
IUPAC Name
tripotassium 2-hydroxypropane-1,2,3-tricarboxylate
SMILES
[K+].[K+].[K+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O

References

General References
  1. Monograph [Link]
  2. safety data sheet [Link]
PubChem Compound
13344
PubChem Substance
310265041
ChemSpider
12775
RxNav
54993
ChEBI
64733
ChEMBL
CHEMBL1200458
Wikipedia
Potassium_citrate
AHFS Codes
  • 40:12.00 — Replacement Preparations
FDA label
Download (81.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentBone Diseases, Metabolic / Postmenopausal Osteoporosis (PMO)1
4CompletedTreatmentDuodenal Ulcer Due to Helicobacter Pylori1
4CompletedTreatmentHigh Blood Pressure (Hypertension)1
4CompletedTreatmentKidney Stones / Urolithiasis1
4Enrolling by InvitationTreatmentKidney Stones1
4RecruitingTreatmentDentin Hypersensitivity / Periodontal Diseases1
4Unknown StatusPreventionUrolithiasis1
3Active Not RecruitingPreventionDistal Renal Tubular Acidosis1
3CompletedTreatmentHealthy Volunteers1
3CompletedTreatmentHypercalciuria / Kidney Stones1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet1.08 g
TabletOral
Syrup1 mg/5mL
Syrup120 mg/5mL
SyrupOral
SolutionOral
Granule, for solutionOral
Tablet, film coated8000 IU
SolutionOral369 mg
SolutionOral216 mg
Syrup50 mg/5mL
Tablet, effervescentOral2170 mg
GranuleOral2157.3 mg
SolutionOral1 g/15mL
SolutionOral750 mg/15mL
TabletOral8.3 mg
SolutionOral27.2 g/100mL
Syrup2 mg/5mL
SolutionOral108.2 mg
SolutionOral66.67 mg/1mL
SolutionOral6.675 g/100mL
Tablet, effervescentOral2.17 g
SolutionOral6 g/100mL
Powder, for solutionOral100 g
SolutionOral300 mcg/100mL
SolutionOral6.6 g/100mL
SolutionOral6.67 g/100mL
SolutionOral66.7 g/100mL
SolutionOral7 g/100mL
SolutionOral9.15 meq/15mL
Tablet, extended releaseOral1080 mg/1
Tablet, extended releaseOral540 mg/1
SolutionOral1.25 g/100mL
Syrup11 g/100mL
TabletOral10 meq/1
TabletOral15 meq/1
TabletOral5 meq/1
SolutionOral0.206 mmol/1mL
SolutionOral11.25 mg/15mL
TabletOral1080 mg
SolutionOral140 mg/1mL
SolutionOral10.8 g/100mL
LiquidOral
Tablet, extended releaseOral
Tablet, extended releaseOral10 meq/1
Tablet, extended releaseOral15 meq/1
Tablet, extended releaseOral5 meq/1
TabletOral540 mg
Tablet, extended releaseOral1080 mg
Tablet231.5 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility39.4 mg/mLALOGPS
logP-0.7ALOGPS
logP-1.3ChemAxon
logS-0.89ALOGPS
pKa (Strongest Acidic)3.05ChemAxon
pKa (Strongest Basic)-4.2ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area140.62 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity68.14 m3·mol-1ChemAxon
Polarizability14.23 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Drug created on September 23, 2015 10:41 / Updated on October 25, 2020 09:16

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates